Delving into the Latest Updates on Febuxostat with Synapse

The goal of this proof-of-concept clinical study is to determine the effect of combining osimertinib with febuxostat on cerebrospinal fluid concentrations of osimertinib in patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC). The main question it aims to answer is: what is the effect of combining osimertinib with the ABCG2 inhibitor febuxostat on cerebrospinal fluid to unbound plasma osimertinib concentration ratio in patients with EGFR mutated NSCLC without central nervous system (CNS) metastases and without the ABCG2 34G>A single nucleotide polymorphism (SNP)?

Start Date01 Jun 2026

Sponsor / Collaborator

Netherlands Cancer Insitute

[+1]

ChiCTR2600123450

/ Not yet recruitingNot ApplicableIIT

The effect of C-cell vitality water in combination with febuxostat on serum urate in patients with gout:a randomized, placebo-controlled ,multicenter clinical trial

Start Date06 May 2026

Sponsor / Collaborator

The Affiliated Hospital of Qingdao University

100 Clinical Results associated with Febuxostat

Login to view more data

100 Translational Medicine associated with Febuxostat

Login to view more data

100 Patents (Medical) associated with Febuxostat

Login to view more data

1,770

Literatures (Medical) associated with Febuxostat

31 Dec 2026·ANNALS OF MEDICINE

A treat-to-target urate management strategy does not improve kidney outcome in patients with chronic kidney disease and asymptomatic hyperuricemia: a target trial emulation

Article

Author: Liu, Qi ; He, Qiang ; Jin, Juan ; He, Wenfang ; Hu, Yibo ; Zheng, Danna ; He, Ran ; Fang, Zihan

BACKGROUND:

Whether a treat-to-target urate management strategy improves kidney outcomes in patients with chronic kidney disease (CKD) and asymptomatic hyperuricemia initiating urate-lowering therapy (ULT) remains uncertain, despite current guidelines.

METHODS:

This target trial emulation (TTE) study included 2092 adults with stage G3-G4 CKD and asymptomatic hyperuricemia who initiated ULT at Zhejiang Provincial People's Hospital between 2018 and 2024. Using a clone-censor-weight (CCW) approach to address biases, we compared a treat-to-target strategy (targeting serum urate <360 μmol/L within 183 days) versus a non-treat-to-target strategy. Patients were followed for up to 3 years. The primary outcome was a composite kidney outcome: end-stage kidney disease (ESKD) or ≥40% eGFR decline.

RESULTS:

The 3-year absolute risk of composite kidney outcome was 33.3% (95% CI, 30.1%-36.6%) under the treat-to-target strategy and 35.8% (95% CI, 30.7%-40.5%) under the non-treat-to-target strategy, yielding a risk difference of -2.5% (95% CI, -6.5% to 2.5%) and a risk ratio of 0.93 (95% CI, 0.83-1.08). Subgroup analyses revealed no heterogeneity, and sensitivity analyses yielded consistent results.

CONCLUSION:

A treat-to-target urate management strategy was not associated with a reduced risk of composite kidney outcomes compared to a non-treat-to-target strategy. Among patients with stage G3-G4 CKD and asymptomatic hyperuricemia in whom clinicians decide to start ULT, these findings do not support pushing to achieve this intensive urate target for improving renal outcomes. As findings are largely based on a febuxostat-dominant real-world setting, extrapolation to other ULT agents may be limited.

01 Dec 2026·JOURNAL OF MOLECULAR MEDICINE-JMM

2,8-Dihydroxyadenine disrupts epithelial integrity and alters kidney cell phenotype in vitro

Article

Author: Gudjonsson, Thorarinn ; Palsson, Runolfur ; Edvardsson, Vidar Orn ; Helgudottir, Hildur Run

Adenine phosphoribosyltransferase (APRT) deficiency is an autosomal recessive disorder that causes accumulation of 2,8-dihydroxyadenine (DHA) in the urinary tract, leading to kidney stones and chronic kidney disease (CKD). Progression to end-stage kidney disease can occur without timely treatment. The xanthine oxidoreductase inhibitors, allopurinol and febuxostat, block DHA generation and halt or delay stone formation and CKD progression. Some patients do not tolerate xanthine oxidoreductase inhibitor treatment, necessitating new therapeutic approaches. This study aimed to investigate how DHA influences structural and molecular changes in HK-2, HEK293, and MDCK kidney cells. DHA exposure reduced cell viability and impaired migration in all cell lines. Increased expression of the adhesion protein CD44 was observed adjacent to DHA crystals in HEK293 and HK-2 cells. Transepithelial electrical resistance measurements in MDCK cells indicated reduced epithelial integrity following DHA exposure. RNA sequencing of DHA-treated HK-2 cells revealed gene expression changes, with upregulation of TNF-α and mTORC1 signaling and downregulation of epithelial to mesenchymal transition and oxidative phosphorylation. Functional enrichment analysis highlighted pathways related to cell cycle regulation, inflammation, and metabolic processes. These findings show that dose-dependent DHA toxicity interrupts cell migration and epithelial integrity. CD44 may contribute to crystal adhesion, and thus, represents a potential therapeutic target in DHA crystal nephropathy. KEY MESSAGES: DHA reduces kidney cell viability and migration in a dose-dependent manner. DHA disrupts epithelial integrity in MDCK cells, lowering TEER values. CD44 expression increases adjacent to DHA crystals with increased DHA concentration. RNA sequencing shows that DHA upregulates TNF-α, mTORC1, and stress pathways. DHA alters gene expression, affecting inflammation, metabolism, and EMT.

01 Dec 2026·JOURNAL OF ETHNOPHARMACOLOGY

Xin-Zi-Sheng-Wan decoction alleviates hyperuricemia-associated renal injury by inhibiting RIPK1/RIPK3/MLKL-mediated necroptosis

Article

Author: Huang, Wendi ; Chen, Jinfang ; Cheng, Jinguo ; Wang, Fangyan ; Bao, Hanxiao ; Qiao, Hongyang ; Fan, Meixia ; Zhu, Liting ; Wang, Zhuoquan ; Zeng, Congcong ; Gao, Yujiu

ETHNOPHARMACOLOGICAL RELEVANCE:

Xin-Zi-Sheng-Wan Decoction (XZSWD) is a modified formulation derived from the classical prescription Zi-Sheng Pill, which was recorded in Xian Xing Zhai Yi Xue Guang Bi Ji from the Ming Dynasty. Traditionally, this formula is used to eliminate "turbid stagnation" and restore metabolic balance. Contemporary ethnopharmacological evidence indicates that XZSWD can reduce uric acid (UA) levels and ameliorate renal injury, although the molecular mechanism underlying these effects remains incompletely understood.

AIM OF THE STUDY:

The aim of this study was to determine whether XZSWD mitigates hyperuricemia-associated renal injury and to elucidate the underlying mechanisms, with a particular focus on RIPK1/RIPK3/MLKL-mediated necroptosis and oxidative stress in vivo and in vitro.

METHODS:

UPLC-QTOF/MS was used to profile XZSWD constituents. A hyperuricemia mouse model was established in C57BL/6J mice using hypoxanthine plus potassium oxonate, followed by XZSWD or febuxostat treatment; serum UA, Cr, and BUN and renal histopathology were assessed, together with Western blot and immunofluorescence. RNA-seq (GSE300922), network pharmacology, and molecular docking were performed to identify key targets and pathways. In vitro, HK-2 cells were treated with tumor necrosis factor-alpha (TNF-α), necroptosis inhibitors, apoptosis inhibitors and XZSWD-medicated serum, and cell viability and Annexin V-FITC/PI flow cytometry were conducted.

RESULTS:

XZSWD lowered serum UA and improved renal function, alleviating tubular injury and fibrosis in hyperuricemic mice. RNA-Seq and network analyses implicated TNF signaling and necroptosis. In HK-2 cells, XZSWD improved viability, reduced reactive oxygen species (ROS) accumulation, and suppressed RIPK1/RIPK3/MLKL phosphorylation, consistent with inhibition of necroptotic cell death.

CONCLUSIONS:

XZSWD ameliorates hyperuricemia-associated renal injury by attenuating TNF-α-driven RIPK1/RIPK3/MLKL-mediated necroptosis and oxidative stress.

39

News (Medical) associated with Febuxostat

13 Aug 2026

·www.biospace.com

JW Pharmaceutical Proves Efficacy of Key 6mg Dose of Gout Treatment ‘Epaminurad’ in Multinational Phase 3 Trial

- Confirms superiority over ‘Febuxostat 40mg’ with excellent serum uric acid-lowering effect - Secures favorable safety pro target product approval in South Korea in 2027 SEOUL, South Korea--(BUSINESS WIRE)-- #Biotechnology -- JW Pharmaceutical (KRX:001060) announced that the multinational Phase 3 clinical trial of its gout treatment candidate ‘Epaminurad (code name URC102)’ demonstrated excellent serum uric acid-lowering effects and statistical superiority for its main development dose of 6mg compared to the existing treatment. Epaminurad is an oral uricosuric agent with a mechanism that selectively inhibits the human uric acid transporter-1 (hURAT1) to suppress the reabsorption of uric acid in the kidneys and promote its excretion. It is a new drug candidate currently under development for patients with hyperuricemia and gout who have abnormally high levels of serum uric acid. This Phase 3 clinical trial was conducted on 612 gout patients across 52 centers in five Asian countries, including South Korea, Taiwan, Thailand, Malaysia, and Singapore. It was designed as a multicenter, randomized, double-blind, active-controlled study to evaluate the efficacy and safety of Epaminurad (6mg, 9mg) in comparison to Febuxostat, an existing uric acid production inhibitor. The analysis of the primary efficacy endpoint—the proportion of patients achieving a serum uric acid (sUA) concentration of less than 6 mg/dL in the last three measurements of the main study period—showed that the Epaminurad 6mg group recorded 50.0% (76/152 patients), demonstrating a higher treatment response rate than the control group, Febuxostat 40mg (38.3%, 59/154 patients). The response rate difference between the two groups was 12.0%p (95% confidence interval 1.26~22.6), satisfying non-inferiority criteria and proving statistical superiority. An excellent pro also confirmed in the safety evaluation. There was no significant difference in the incidence of Treatment-Emergent Adverse Events (TEAEs) between the Epaminurad and Febuxostat groups during the treatment period. The incidence rates of Adverse Drug Reactions (ADRs), Serious Adverse Events (SAEs), Serious Adverse Drug Reactions (SADRs), and Adverse Events of Special Interest (AESIs) also showed similar levels. No drug-related deaths were reported during the clinical trial period. The high-dose 9mg group did not meet the statistical non-inferiority criteria for the primary efficacy endpoint compared to Febuxostat 80mg. However, the proportion of patients achieving a serum uric acid (sUA) concentration of less than 6 mg/dL in the last three measurements of the main study period was 59.6% (87/146 patients) in the Epaminurad 9mg group and 63.3% (95/150 patients) in the Febuxostat 80mg group, with a response rate difference of approximately 4%p between the two groups. Based on the overall clinical data and subgroup analysis results for the high dose, JW Pharmaceutical plans to further review the efficacy pro specific patient populations and explore approval strategies for the high dose. Based on these clinical results, JW Pharmaceutical plans to proceed with a New Drug Application (NDA) aiming for regulatory approval in South Korea in 2027. Epaminurad was selected as a pilot project for the South Korean Ministry of Food and Drug Safety (MFDS)'s ‘New Drug Approval and Evaluation Innovation Plan,’ and completed two ‘Pre-NDA meetings’ last July. In addition, the company plans to pursue out-licensing opportunities for global market entry continuously. Eun-Kyung Hahm, CEO of JW Pharmaceutical, stated, “There is a substantial unmet need for new treatment options due to the increase in gout patients and safety concerns regarding existing treatments.” She added, “As we have proven superior efficacy and a favorable safety pro to Febuxostat 40mg, the most prescribed in the South Korean gout treatment market, we will concentrate our capabilities on preparing the product approval process without a hitch so that Epaminurad can establish itself as a Best-in-Class drug.” According to a pharmaceutical market research firm UBIST, the South Korean gout treatment market is estimated at approximately 41.1 billion KRW as of 2025. Febuxostat products lead the market with roughly 34.7 billion KRW (84.4%), with Febuxostat 40mg accounting for over 63% of the entire market, with prescription sales of about 26 billion KRW. A global market research firm Grand View Research expects the global gout treatment market to grow from approximately USD 2.8 billion in 2024 to USD 4.1 billion in 2030. (USD 1 = KRW 1,411) About JW Pharmaceutical Founded in 1945, JW Pharmaceutical Corporation has been a leader in Korea’s therapeutic pharmaceutical market, guided by its founding principles of respect for life and a spirit of challenge. With a robust portfolio of original medicines, JW Pharmaceutical has focused on innovative drug discovery and development since establishing its Central Research Institute in 1983 and the C&C Research Laboratories in 1992. Through advanced research technologies, including its AI-based drug discovery and development platform, JWave, the company has built a strong pipeline in oncology, immunology, and regenerative medicine. JW Pharmaceutical also actively pursues diverse research initiatives aligned with global trends through open innovation. JW Pharmaceutical Corporation is listed on the Korea Exchange under the ticker “001060.” Contacts JW Pharmaceutical Jung-jae Yoo Head of PR, Corporate Communications jw_pr@jw-group.co.kr

Phase 3Clinical ResultNDA

22 Jul 2026

·www.biopharmadive.com

Crystalys nets $130M more to push gout drug through late-stage tests

Less than a year after landing a big funding round, Crystalys Therapeutics has banked a second one, announcing Wednesday a $130 million Series B to support global late-stage tests, and launch preparations, for a gout drug its been working on.Launched last September with a $205 million Series A, Crystalys received support in its newest financing from more than 20 firms, many of which are the kind of crossover investors that back private as well as publicly traded companies. Frazier Life Sciences led the round, and firms like Wellington Management, Cormorant Asset Management, SR One and Novo Holdings pitched in.Crystalys views its drug, dotinurad, as a potential best-in-class treatment for gout, a type of arthritis caused by a buildup of uric acid in the body. While a therapy called allopurinol has long been the treatment standard for gout which causes sudden flares of joint pain it doesnt work for many people and the options behind it are flawed. Amgens Krystexxa comes with a high cost and requires twice-weekly infusions. Another treatment, known as febuxostat, is linked with potential heart problems.Dotinurad represents a different potential solution. Originally discovered by Japanese drugmaker Fuji Yakuhin, its is designed to inhibit a transporter protein called URAT1 that regulates uric acid levels. Dotinurad was approved in Japan in 2020 and, since then, has been cleared in China where Eisai owns rights as well as the Philippines and Thailand.Crystalys acquired U.S. and European rights to the treatment from a subsidiary of Fortress Bio in 2024. Its since ushered the therapy into two global trials in people with severe gout cases or excess uric acid. Both are evaluating dotinurad against allipurinol over the course of 24 weeks, and should deliver results next year.The company has also started a Phase 2 trial in people who either cant tolerate allopurinol or similar drugs, or havent responded to therapies like Krystexxa.This financing strengthens our ability to advance our [trials] and positions Crystalys to achieve multiple important clinical and regulatory milestones and commercial readiness as we work to bring a potentially best-in-class treatment option to patients living with gout, said Crystalys CEO James Mackay, in a statement.Crystalys is betting that dotinurad is a clear improvement over an old AstraZeneca drug called Zurampic, which also inhibited URAT1. Zurampic gained approval in 2015 but was associated with kidney damage and later withdrawn because of low sales. In an interview with BioPharma Dive last year, Mackay noted that dotinurad binds to its target more precisely and could better protect the kidneys.Because dotinurad is an established drug, Crystalys was able to persuade the Food and Drug Administration to allow it to go straight into late-stage development without amassing the usual early safety and efficacy data. '

Drug ApprovalPhase 2

21 Jul 2026

·www.fiercebiotech.com

Crystalys mines $130M series B to push gout drug through phase 3

Crystalys Therapeutics has raised $130 million in series B financing to advance the development of its gout drug dotinurad and prepare for a potential commercial launch. The financing comes less than a year after Crystalys emerged from stealth with an impressive $205 million series A round in September 2025. Frazier Life Sciences led the latest round, with participation from new investors Wellington Management, HBM Healthcare Investments, Soleus Capital and Cormorant Asset Management, among others. All of Crystalys’ existing investors also participated, including Novo Holdings, SR One and Catalys Pacific. “It was one of the fastest financings that I've ever participated in,” Crystalys CEO James Mackay, Ph.D., told Fierce. “Last year we raised our $205 million series A. I think that made a lot of investors who didn't participate in that sit up and take notice.” The proceeds will support two ongoing, registration-directed phase 3 trials, as well as the phase 2 Amethyst study. Crystalys also plans to use the money to prepare for dotinurad’s potential commercialization. The financing is expected to extend the company’s runway through multiple clinical and regulatory milestones. Dotinurad is a once-daily oral inhibitor of urate transporter 1 (URAT1), designed to help the kidneys excrete uric acid. Excess uric acid can lead to the formation of crystals in the joints, causing the painful inflammation associated with gout. Mackay described dotinurad as an extremely “de-risked molecule” because it has already been approved in several Asian markets. The drug, originally developed by Japanese drugmaker Fuji Yakuhin, is approved in Japan, China, the Philippines, Taiwan and Thailand. Crystalys acquired the rights to dotinurad from Urica Therapeutics in July 2024. In exchange, Urica received common stock representing 35% of Crystalys’ outstanding equity and a 3% royalty on future net sales. Drawing on clinical data generated in Asia and earlier U.S. studies, Crystalys secured regulators’ support to move directly into late-stage development in the U.S. and Europe. The phase 3 Ruby trial is comparing dotinurad with allopurinol in patients with hyperuricemia associated with gout, while the phase 3 Topaz trial is evaluating the same treatments in patients with tophaceous gout. FDA-approved urate-lowering treatments include the xanthine oxidase inhibitors allopurinol and febuxostat. Febuxostat’s label carries a boxed warning about an increased risk of cardiovascular death in patients with established cardiovascular disease and limits its use to patients who do not respond adequately to allopurinol, cannot tolerate it or should not receive it. Mackay said roughly half of patients treated with existing first-line drugs reach their treatment goals. For patients whose chronic gout remains uncontrolled despite treatment with xanthine oxidase inhibitors, one option is Krystexxa, an intravenous therapy administered every two weeks alongside weekly methotrexate. “There's a massive unmet medical need in the second line space,” Mackay told Fierce. San Diego-based Crystalys was formed in 2022 and co-founded by Mackay, Novo Holdings, Catalys Pacific and other members of its leadership team. Mackay previously led Aristea Therapeutics, an AstraZeneca spinout that shut down in 2023 after safety concerns emerged in a clinical trial of its lead inflammatory disease drug. Before that, he led Ardea Biosciences and helped develop Zurampic, the first URAT1 inhibitor approved in the U.S. Now, with dotinurad in late-stage development and Crystalys newly flush with cash, Mackay is considering the company’s longer-term financing options. With the biotech market “reasonably buoyant” at the moment, he said Crystalys could pursue an IPO. For now, he expects the series B proceeds to give the company enough cash to operate “at least a year beyond the phase 3 data readouts.”

100 Deals associated with Febuxostat

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01206	Febuxostat	M04AA03	DB04854

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Arthritis, Gouty	European Union	Viatris Ltd. (New Zealand)	15 Jun 2017
Arthritis, Gouty	Iceland	Viatris Ltd. (New Zealand)	15 Jun 2017
Arthritis, Gouty	Liechtenstein	Viatris Ltd. (New Zealand)	15 Jun 2017
Arthritis, Gouty	Norway	Viatris Ltd. (New Zealand)	15 Jun 2017
HYPERURICEMIA CHRONIC	European Union	Viatris Ltd. (New Zealand)	15 Jun 2017
HYPERURICEMIA CHRONIC	Iceland	Viatris Ltd. (New Zealand)	15 Jun 2017
HYPERURICEMIA CHRONIC	Liechtenstein	Viatris Ltd. (New Zealand)	15 Jun 2017
HYPERURICEMIA CHRONIC	Norway	Viatris Ltd. (New Zealand)	15 Jun 2017
Gout	United States	Takeda Pharmaceuticals U.S.A., Inc.	13 Feb 2009
Hyperuricemia	European Union	Menarini International Operations Luxembourg SA	21 Apr 2008
Hyperuricemia	Iceland	Menarini International Operations Luxembourg SA	21 Apr 2008
Hyperuricemia	Liechtenstein	Menarini International Operations Luxembourg SA	21 Apr 2008
Hyperuricemia	Norway	Menarini International Operations Luxembourg SA	21 Apr 2008

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hematologic Neoplasms	Phase 3	-	A.Menarini Industrie Farmaceutiche Riunite Srl	01 Oct 2012
Tumor Lysis Syndrome	Phase 3	-	A.Menarini Industrie Farmaceutiche Riunite Srl	01 Oct 2012
Cardiovascular Abnormalities	Phase 3	United States	Takeda Pharmaceutical Co., Ltd.	23 Apr 2010
Cardiovascular Abnormalities	Phase 3	Mexico	Takeda Pharmaceutical Co., Ltd.	23 Apr 2010
Primary gout	Phase 3	-	Takeda Pharmaceutical Co., Ltd.	01 Jul 2002
Angina, Stable	Phase 2	United States	Takeda Pharmaceutical Co., Ltd.	01 Jul 2012
Hypertension	Phase 2	United States	Takeda Pharmaceutical Co., Ltd.	01 Feb 2012
Kidney Calculi	Phase 2	United States	Takeda Pharmaceutical Co., Ltd.	01 Feb 2010
Nephrolithiasis, Calcium Oxalate	Phase 2	United States	Takeda Pharmaceutical Co., Ltd.	01 Feb 2010
Brain Infarction	Clinical	Japan	Teijin Pharma Ltd.	01 Nov 2013

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06414837 (EULAR2026)	Phase 3	Gout \| Hyperuricemia	442	HR091506	qjsoxqanyb(yekrkqswmc) = ewtuqnqvhz weflvdgquu (zlnemqzzfm, 57.5 - 70.1) View more	Positive	11 Jun 2026
				Febuxostat + Febuxostattion(20-80mg)	qjsoxqanyb(yekrkqswmc) = swfwwhdaxv weflvdgquu (zlnemqzzfm, 34.2 - 47.2) View more
EULAR2026	Not Applicable	Gout	1,570	Dotinurad 4 mg/day	wctkfyutpv(vkjvtspdxr): OR = 4.56 (95.0% CI, 3.06 - 6.89) View more	Positive	11 Jun 2026
				Febuxostat 40 mg/day
STOP Gout (ACR2025)	Phase 3	Gout	940	Allopurinol	mjugdadnfo(swvkucqzss) = opubjmkyso oturcryfka (jhoumeqtlg )	Positive	24 Oct 2025
				Febuxostat	mjugdadnfo(swvkucqzss) = jkigrragtx oturcryfka (jhoumeqtlg )
ACR2025	Not Applicable	Gout	409	Allopurinol	pmqsyzxgai(efqfatwimd) = nmkjbmcgtu zzfamlzxpr (iomtclcrdc ) View more	Negative	24 Oct 2025
NCT05574036 (Pubmed \| Eur J Pharmacol)	Phase 2	Metabolic dysfunction-associated steatotic liver disease NLRP-3 \| TIM-3 \| HOMA-IR ... View more	-	Febuxostat 80 mg	eicxceacpw(wcdgsjvgrb) = cjailuszro jhkzcgvipb (khwzytwnse )	Positive	01 Aug 2025
				Vitamin E 400 mg	eicxceacpw(wcdgsjvgrb) = tudorccinn jhkzcgvipb (khwzytwnse )
ASN2023	Not Applicable	Chronic Kidney Diseases	4,379	Febuxostat	idejupvkhh(mtgepiitym) = sdxfawnbhw cwywidjkby (arcuurqdda ) View more	Positive	02 Nov 2023
				Allopurinol	idejupvkhh(mtgepiitym) = bmmqdbooxp cwywidjkby (arcuurqdda ) View more
TCTR20210224005 (Pubmed \| Sci Rep)	Phase 4	Chronic Kidney Diseases	84	Febuxostat	fvtuetvzxz(ubcskjhued) = zvkqrwkfcv hynvpabick (bjtrnpwixt, 0.31 - 3.7)	-	18 Aug 2023
				febuxostat (Control)	fvtuetvzxz(ubcskjhued) = xlpdlhgtwi hynvpabick (bjtrnpwixt, -1.52 to 1.61)
ASN2022	Not Applicable	Hyperuricemia \| Hypertension \| Chronic Kidney Diseases hyperuricemia \| hypertension	96	Febuxostat	godhhwswuv(moiphplbhq) = asntlpluya suhvhqzxtm (ptgupnjtsa, -2.00 to 1.55)	Negative	05 Nov 2022
				Benzbromarone	-
NCT04157959 (Pubmed \| J Clin Pharmacol)	Not Applicable	Lesch-Nyhan Syndrome	-	SHR4640 10 mg	jpmygarowl(qimctohggl) = fawoflxclc izpvimxeep (kywutonyhf )	-	21 Sep 2022
				SHR4640 10 mg + Febuxostat 80 mg	jpmygarowl(qimctohggl) = bzrgkpzmdv izpvimxeep (kywutonyhf )
EULAR2022	Not Applicable	Gout	-	Febuxostat	hgotybqliw(ezvbpppjil): HR = 1.1 (95% CI, 0.96 - 1.26) View more	-	01 Jun 2022
				Allopurinol